{"title":"Model-based fed-batch cultivation of <i>Viola odorata</i> plant cells exhibiting antimalarial and anticancer activity.","authors":"R Babu, Manokaran Veeramani, Wallepure Aadinath, Vignesh Muthuvijayan, Shailja Singh, Smita Srivastava","doi":"10.3389/fbioe.2025.1528570","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>Viola odorata</i> is a medicinal plant used in the indigenous systems of medicine in India, to treat respiratory tract disorders. <i>V. odorata</i> natural plant source is limited in availability. Bioprocess principles can be applied to develop sustainable methods for the commercial production of high-quality <i>V. odorata</i> plant biomass.</p><p><strong>Methods: </strong>To this effect, the <i>in vitro</i> culture conditions of <i>V. odorata</i> were rationally optimized to increase the biomass production up to 21.7 ± 0.8 g DW L<sup>-1</sup> in 12 days in shake flasks. In the current study, a modified stirred tank reactor and a balloon-type bubble column reactor were used to improve the biomass production at the batch reactor level. Sufficient nutrient feeding strategies were developed using first principle-based mathematical modelling to overcome substrate inhibition and achieve higher cell density in the reactor. In addition, bioreactor-cultivated biomass extracts (aqueous/alcoholic) were tested for various bioactivities like hemolytic, cytotoxic, anti-inflammatory, and antiplasmodial.</p><p><strong>Results: </strong>Experimental validation of the fed-batch model-predicted strategy resulted in a two-fold enhancement in biomass production (32.2 g DW L<sup>-1</sup>) at the bioreactor level. Biomass extracts showed no hemolytic activity up to 4 mg mL<sup>-1</sup> concentrations. Further, the stirred tank cultivated biomass extract displayed cytotoxicity against Caco2 - colon carcinoma cell lines, exhibiting an IC50 of 1.5 ± 0.1 mg mL<sup>-1</sup>. <i>In vitro</i> experiments also indicated the anti-inflammatory property in the bioreactor cultivated plant biomass extracts. As a new application, the biomass extracts also demonstrated up to 80% inhibition of malarial parasite growth <i>in vitro</i>. Additionally, when administered alongside artesunate (1.8 mg kg<sup>-1</sup>d<sup>-1</sup>), the plant extracts (400 mg kg<sup>-1</sup>d<sup>-1</sup>) effectively controlled parasite growth <i>in vivo</i>.</p><p><strong>Discussion: </strong>It is to be noted that a first report on fed-batch cultivation of <i>V. odorata</i> cell suspension culture in lab-scale bioreactors and on the antiplasmodial activity of the <i>V. odorata</i> plant extracts. Overall, the bioactive potential of the <i>in vitro</i>-generated plant biomass extracts is similar to that in the natural plant biomass extracts.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1528570"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815595/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1528570","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Viola odorata is a medicinal plant used in the indigenous systems of medicine in India, to treat respiratory tract disorders. V. odorata natural plant source is limited in availability. Bioprocess principles can be applied to develop sustainable methods for the commercial production of high-quality V. odorata plant biomass.
Methods: To this effect, the in vitro culture conditions of V. odorata were rationally optimized to increase the biomass production up to 21.7 ± 0.8 g DW L-1 in 12 days in shake flasks. In the current study, a modified stirred tank reactor and a balloon-type bubble column reactor were used to improve the biomass production at the batch reactor level. Sufficient nutrient feeding strategies were developed using first principle-based mathematical modelling to overcome substrate inhibition and achieve higher cell density in the reactor. In addition, bioreactor-cultivated biomass extracts (aqueous/alcoholic) were tested for various bioactivities like hemolytic, cytotoxic, anti-inflammatory, and antiplasmodial.
Results: Experimental validation of the fed-batch model-predicted strategy resulted in a two-fold enhancement in biomass production (32.2 g DW L-1) at the bioreactor level. Biomass extracts showed no hemolytic activity up to 4 mg mL-1 concentrations. Further, the stirred tank cultivated biomass extract displayed cytotoxicity against Caco2 - colon carcinoma cell lines, exhibiting an IC50 of 1.5 ± 0.1 mg mL-1. In vitro experiments also indicated the anti-inflammatory property in the bioreactor cultivated plant biomass extracts. As a new application, the biomass extracts also demonstrated up to 80% inhibition of malarial parasite growth in vitro. Additionally, when administered alongside artesunate (1.8 mg kg-1d-1), the plant extracts (400 mg kg-1d-1) effectively controlled parasite growth in vivo.
Discussion: It is to be noted that a first report on fed-batch cultivation of V. odorata cell suspension culture in lab-scale bioreactors and on the antiplasmodial activity of the V. odorata plant extracts. Overall, the bioactive potential of the in vitro-generated plant biomass extracts is similar to that in the natural plant biomass extracts.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.